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ABSTRACT
Quaking (QKI) is a tumor-suppressor gene encoding a conserved RNA-binding 
protein, whose expression is downregulated in several solid tumors. Here we 
report that QKI plays an important role in the immune response and suppression of 
leukemogenesis. We show that the expression of Qki is reduced in lipopolysaccharide 
(LPS)-challenged macrophages, suggesting that Qki is a key regulator of LPS signaling 
pathway. Furthermore, LPS-induced downregulation of Qki expression is miR-155-
dependent. Qki overexpression impairs LPS-induced phosphorylation of JNK and 
particularly p38 MAPKs, in addition to increasing the production of anti-inflammatory 
cytokine IL-10. In contrast, Qki ablation decreases Fas expression and the rate 
of Caspase3/7 activity, while increasing the levels of IL-1α, IL-1β and IL-6, and 
p38 phosphorylation. Similarly, the p38 pathway is also a target of QKI activity in 
chronic lymphocytic leukemia (CLL)-derived MEC2 cells. Finally, B-CLL patients show 
lower levels of QKI expression compared with B cells from healthy donor, and Qki is 
similarily downregulated with the progression of leukemia in Eµ-miR-155 transgenic 
mice. Altogether, these data implicate QKI in the pathophysiology of inflammation 
and oncogenesis where miR-155 is involved.
INTRODUCTION
miR-155 is an oncogenic pro-inflammatory 
microRNA (miRNA) that is up-regulated in a number 
of solid tumors and liquid malignancies [1-3]. High 
levels of miR-155 often correlate with a poor prognosis 
[4-5]. Targeted expression of miR-155 in B cells results 
in pre-B cell acute leukemia/high-grade lymphoma [6]. 
Furthermore, overexpression of miR-155 in lymphoid 
tissues results in disseminated lymphoma characterized 
by a clonal, transplantable pre-B-cell population of 
neoplastic lymphocytes “addicted” to miR-155-activity 
[7]. In hematopoietic cells, the expression of miR-155 is 
controlled by several immune signals [1-3]. Thus, LPS 
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induces miR-155 expression in macrophage/monocytic 
cell lines of both mouse and human origin [8-9]. The 
oncogenic and pro-inflammatory effects of miR-155 
have been attributed at least in part to its targeting of 
many transcripts encoding tumor suppressors and/or anti-
inflammatory factors, especially Ship1 [10-12], Socs1 
[13].
Quaking (QKI, KH domain containing, RNA 
binding) is a member of the signal transduction and 
activation of RNA (STAR) family of RNA-binding 
proteins. Three major QKI isoforms (QKI-5, QKI-6 and 
QKI-7), each with a specific carboxy-terminal end, are 
produced through alternative splicing both in mouse and 
human [14]. QKI-5 contains a nuclear localization signal, 
is predominantly localized in the nucleus, and is most 
likely to function in pre-mRNA splicing or RNA retention. 
In contrast, QKI-6 is localized in both the nucleus and the 
cytoplasm, while QKI-7, exclusively cytoplasmic, is pro-
apoptotic [14-16]. QKI behaves as a tumor suppressor 
gene (TSG) in glioblastoma multiforme (GBM) [17]. 
QKI, under the direct control of p53 in GBM cells [17], is 
also downregulated in gastric and colon cancers [18-19]. 
In GBM cells, QKI can associate with and stabilize miR-
20a, thus, increasing miR-20a down-regulatory effects 
on TGF-β receptor type II (TGF-βR2), whose activity is 
oncogenic in gliomagenesis [17].
As QKI is the first most probable target of miR-155 
in apes and human (targetscan.org), and that the expression 
of miR-155 is upregulated in glioblastomas [20-21], the 
above-mentioned facts suggested that miR-155 might carry 
out its oncogenic and pro-inflammatory functions at least 
in part by targeting QKI. In the present study, we show that 
(i) QKI is indeed a target of miR-155 in B cells; (ii) the 
expression of QKI is lower in B-cells from CLL patients 
compare to B cells from healthy donors, and acts as TSG 
also in CLL; (iii) Qki is a target of LPS signaling, and 
its expression is downregulated following LPS challenge 
of macrophages; (iv) Qki modulates downstream LPS 
signaling in return; particularly p38 MAPK activation and 
IL-10 production, thus presenting with anti-inflammatory 
properties. We propose that miR-155 and QKI form a 
critical regulatory component downstream of TLR4 in 
target hematopoietic cells, and that miR-155 exerts its 
pro-inflammatory and oncogenic activities at least in part 
through the downregulation of QKI expression. 
RESULTS
QKI is downregulated at the onset of the innate 
immune response to LPS
We have previously shown that the expression 
of miR-155 is upregulated in mouse RAW-264.7 
macrophages treated with LPS [8]. As Qki is a potential 
Figure 1: QKI expression is downregulated at the onset 
of LPS challenge. A.-C. Qki, miR-155 and Tnf levels in 
RAW-264.7 cells were measured by qRT-PCR (n = 3); A.: *P 
= 0.0636; **P < 0.000345. B.: *P = 0.06177; **P = 0.03106; 
***P < 0.00168. C.: *P = 0.0124; **P < 0.000786. D. RAW-
264.7 cells transfected with either a Control-RNA (Control) or 
an antisense miR-155 inhibitory RNA (155-I) were challenged 
with LPS 24 hours later. Qki transcripts levels were measured by 
qRT-PCR (n = 3). *miR-155-I different from Control, P < 0.037. 
# 8-hours different from 4-hours, P < 0.0052. o12-hours different 
from 8-hours, P < 0.0044.
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target of miR-155, we monitored the expression of Qki, 
using a probe spanning exons 4 and 5 that recognizes all 
Qki isoforms, as well as of miR-155 and Tnf in mouse 
RAW-264.7 macrophages following LPS stimulation. 
Qki expression decreased 2-fold within 4 hours, while 
the expression of miR-155 as well as that of Tnf, both 
immediate downstream targets of LPS signaling, increased 
significantly (Figure 1A-1C). Beyond 12 hours, Qki 
transcripts progressively returned to their initial level at 
2-days, while miR-155 level kept increasing. Of note, the 
expression of Qki in untreated cells subsequently increased 
above its initial level, an effect delayed by roughly 
12 hours following LPS challenge (Figure 1A). This 
increase was probably related to the surge of cell density, 
as previously reported in HT29 colon cancer cells [22]. 
Semi-quantitative RT-PCR analysis using oligonucleotides 
designed to specifically recognize each of Qki isoforms, 
showed that both Qki-5 and Qki-6 are expressed in RAW-
264.7 cells and their expression is downregulated at the 
beginning of LPS challenge (data not shown), further 
confirming our hypothesis. On Western blots, Qki levels 
also decreased significantly only for a short period of time 
(data not shown), suggesting that Qki might be a critical 
component of LPS signaling, potentially involved in 
preventing the initiation of an unnecessary innate immune 
response, assuring the robustness of the response at its 
onset, and resolving and terminating the response later on. 
Our pan-Qki antibody detected one Qki isoform only, and 
QKI-5 being the main isoform expressed in hematopoietic 
cells [23], this isoform is likely to represent Qki-5.
Accordingly, an antisense miR-155 inhibitory RNA 
(155-I) protected Qki transcript from downregulation only 
during the first 4 hours of LPS challenge, while remaining 
without effects later on (Figure 1D). Altogether, the above 
results suggest that, in RAW-264.7 macrophages, Qki 
transcripts are potentially targets of miR-155 at the onset 
of LPS signaling only.
Figure 2: QKI is a direct target of miR-155 in human U937 monocytes. A. Schematic (not-to-scale) representation of human 
QKI-3’-UTR. The sequences of miR-155 consensus target sites (highlighted) present in the three QKI-3’-UTR Luciferase reporter constructs 
are shown. B. Cells were co-transfected with either QKI-UTR-1, QKI-UTR-2 or QKI-UTR-3, each containing either a wild type (WT) or 
a mutated (Mut) miR-155 target site, along with either pre-miR-Control (Control) or pre-miR-155 (n = 12). C. Cells were transfected with 
either WT/Mut QKI-UTR-1, QKI-UTR-2 or QKI-UTR-3 24 hours before LPS challenge (n = 12). Values for pre-miR-Control B. and Mock 
C. were arbitrarily set to 1. Assays were performed three times in quadruplicates 48 hours after transfection. B. *miR-155 different from 
Control, P < 0.00052. C. *LPS different from Mock C., P < 0.0022. B., C. #Mutant different from WT, P < 1x10-6.
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QKI is a direct target of miR-155 in U937 cells
Human QKI-3’-UTR contains three putative miR-
155 target sites, the first one being conserved among 
eutherian mammals but absent in muridae and in some 
human isoforms, the second highly conserved across 
vertebrates, and the third one primate-specific (targetscan.
org). To determine whether miR-155 could directly target 
QKI transcripts, we prepared three Luciferase reporter 
constructs from human QKI-3’-UTR, each containing 
one miR-155 target site (Figure 2A). A miR-155 mimic 
co-transfected in U937 cells with each of these constructs 
decreased the Luciferase activity produced from the 
constructs containing a WT, but not a mutant, miR-155 
site (Figure 2B). Finally, the Luciferase activity also 
decreased when U937 cells were first transfected with 
constructs containing the WT, but not the mutant, miR-
155 site and then challenged with LPS (Figure 2C), giving 
a further evidence that QKI downregulation at the onset of 
the innate immune response to LPS results from its direct 
targeting by miR-155. Intriguingly, mutating the miR-
Table 1: The twenty most significant pathways affected by siQI transfection in MEC2 CLL cells
Rank Ingenuity Canonical Pathways P-value Transcripts
1 Role of Oct4 in Mammalian Embryonic Stem Cell Pluripotency 1.05E-03
FAM208A, RARA, MEF2A, 
IGF2BP1
2 T Helper Cell Differentiation 5.13E-03 TGFBR1, CD80, HLA-DOB, CXCR5
3 Notch Signaling 6.46E-03 ADAM17, DTX3, JAG1
4 Cardiac Hypertrophy Signaling 7.41E-03 ROCK2, GNAS, TGFBR1, IGF1, IRS1, SOS1, MEF2A
5 Role of NFAT in Regulation of the Immune Response 7.59E-03
GNAS, CD80, SOS1, MEF2A, 
HLA-DOB, ITPR1
6 PPARα/RXRα Activation 8.71E-03 GNAS, TGFBR1, GPD2, IRS1, SOS1, ACVR2B
7 TGF-β Signaling 9.77E-03 TGFBR1, SOS1, ACVR2B, SMAD5
8 Role of NFAT in Cardiac Hypertrophy 1.02E-02 GNAS, TGFBR1, IGF1, SOS1, MEF2A, ITPR1
9 Chronic Myeloid Leukemia Signaling 1.48E-02 TGFBR1, CTBP2, SOS1, E2F5
10 IGF-1 Signaling 1.62E-02 NEDD4, IGF1, IRS1, SOS1
11 Cholecystokinin/Gastrin-mediated Signaling 1.86E-02 ROCK2, SOS1, MEF2A, ITPR1
12 β-alanine Degradation I 2.00E-02 ABAT
13 Glycine Degradation (Creatine Biosynthesis) 2.00E-02 GATM
14 Antiproliferative Role of TOB in T Cell Signaling 2.75E-02 TGFBR1, TWSG1
15 Glycerol-3-phosphate Shuttle 2.95E-02 GPD2
16 4-aminobutyrate Degradation I 2.95E-02 ABAT
17 GDNF Family Ligand-Receptor Interactions 3.09E-02 IRS1, SOS1, ITPR1
18 p38 MAPK Signaling 3.09E-02 TGFBR1, MAPT, MEF2A, IRAK3
19 IL-4 Signaling 3.80E-02 IRS1, SOS1, HLA-DOB
20 B Cell Development 4.07E-02 CD80, HLA-DOB
Transcripts whose levels also changed in BJAB Burkitt’s cells are given in bold letters.
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155 target site of QKI-UTR-1 increased the Luciferase 
activity produced following miR-155 transfection beyond 
that of the Control (Figure 2B, 2C). This may possibly 
result from miR-155 targeting immune factor(s) that bind 
to this particular region of Qki-3’-UTR, given that the 
stability of several immune transcripts is regulated by the 
Table 2: The twenty most significant pathways affected by siQI  transfection in BJAB Burkitt’s cells
Rank Ingenuity Canonical Pathways P-value Transcripts
1 Dendritic Cell Maturation 2.69E-05 COL1A1, CD80, PIK3CG, IL32, FSCN1, AKT3, LTB, IL1B, TLR3, CCR7
2 Lymphotoxin β Receptor Signaling 3.02E-04 VCAM1, PIK3CG, AKT3, LTB, TRAF1
3 Crosstalk between Dendritic Cells and Natural Killer Cells 4.57E-04 CD80, CD69, FSCN1, LTB, TLR3, CCR7
4 NF-κB Signaling 4.90E-04 TGFBR1, HDAC2, PIK3CG, IGF1R, AKT3, IL1B, TLR3, TNFRSF17
5 Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis 5.50E-04
VCAM1, C5AR1, PIK3CG, IL32, RAC1, 
AKT3, LTB, IL1B, TLR3, WNT5A, 
TRAF1
6 Docosahexaenoic Acid (DHA) Signaling 8.51E-04 PIK3CG, AKT3, IL1B, APP
7 Hepatic Fibrosis / Hepatic Stellate Cell Activation 8.51E-04 COL1A1, VCAM1, TGFBR1, TIMP1, IGF1R, IL1B, CCR7
8 Role of Tissue Factor in Cancer 1.38E-03 PIK3CG, EGR1, RAC1, ITGA6, AKT3, IL1B
9 Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 2.51E-03 CD80, LTB, IL1B, TLR3, TNFRSF17
10 RAR Activation 3.09E-03 GNAS, DHRS9, PIK3CG, RAC1, AKT3, SMAD5, RXRA
11 Communication between Innate and Adaptive Immune Cells 3.24E-03 CD80, IL1B, TLR3, CCR7, TNFRSF17
12 Human Embryonic Stem Cell Pluripotency 3.55E-03 GNAS, TGFBR1, PIK3CG, AKT3, SMAD5, WNT5A
13 Regulation of the Epithelial-Mesenchymal Transition Pathway 3.80E-03
TGFBR1, PIK3CG, EGR1, ZEB2, 
PARD6B, AKT3, WNT5A
14 Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses 4.07E-03 CLEC7A, C5AR1, PIK3CG, IL1B, TLR3
15 CXCR4 Signaling 6.76E-03 MYL12A, GNAS, PIK3CG, EGR1, RAC1, AKT3
16 Sphingosine-1-phosphate Signaling 7.24E-03 GNAS, PIK3CG, RAC1, AKT3, ASAH1
17 Role of NANOG in Mammalian Embryonic Stem Cell Pluripotency 7.41E-03
PIK3CG, AKT3, SMAD5, WNT5A, 
TCL1A
18 Small Cell Lung Cancer Signaling 7.59E-03 PIK3CG, AKT3, RXRA, TRAF1
19 NF-κB Activation by Viruses 8.71E-03 PIK3CG, ITGA6, AKT3, CXCR5
20 PTEN Signaling 9.33E-03 TGFBR1, PIK3CG, IGF1R, RAC1, AKT3
Transcripts whose levels also changed in MEC2 CLL cells are given in bold letters.
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fixation of RNA binding proteins on their 3’-UTR, and 
that we observed a similar phenomenon in RAW264.7 
macrophages, but not in HEK-293 kidney cells (not 
shown).
Qki regulates cytokine production and MAPK 
phosphorylation
Qki being a target of LPS signaling suggested that 
Qki itself might be a modulator of the innate immune 
response. We thus transfected RAW-246.7 cells with 
a construct expressing QKI-5 (hereafter referred to as 
QKI), chosen because: (i) it is the only QKI isoform 
that contains a nuclear localization signal and functions 
in pre-miRNA splicing and/or RNA retention [15], thus 
being the most likely isoform to impact the stability and 
processing of immune transcripts; and (ii) QKI-5 is the 
main isoform expressed in hematopoietic progenitors and 
differentiated cells [23], and our experiments in Figure 
1 showed that it is well expressed in RAW-264.7 cells. 
Indeed, the over-expression of QKI-5 doubled the level 
of anti-inflammatory IL-10 in cell supernatant (Figure 
3A), 24 hours after LPS challenge. In contrast, targeting 
Qki transcripts with small interfering RNAs (siQKI), 
lead to higher levels of inflammatory IL-1α, IL-1β, IL-6 
and GM-CSF (Figure 3B). The fact that QKI enhanced 
IL-10 production, suggests that its downregulation 
during the first hours of LPS challenge is a prerequisite 
for the immune response to reach the optimal threshold 
level of activation. As LPS binding to TLR4 receptors 
triggers the downstream activation of ERK, JNK and 
p38 MAPK pathways in responding cells [24], we then 
analyzed the effects of QKI on the three above pathways. 
Overexpressing QKI impaired the phosphorylation of 
p38 and Jnk1/Sapk MAPKs, possibly also slightly the 
phosphorylation of Erk1, 2, during the two first hours of 
LPS challenge (Figure 3C). In contrast, siQKI respectively 
increased p38 phosphorylation by 47% at 0.5-hour (P = 
0.0011) and by 177% at 1-hour (P = 0.0789) (Figure 3D), 
as determined by scanning the bands on blots representing 
three different biological replicates. Noteworthy, QKI 
Figure 3: QKI impairs Mapk activation and interleukin production (A-D) RAW-264.7 cells were challenged with LPS 
24 hours following transfection with either an empty CMV vector (Empty) or a construct expressing human QKI-5 (QKI) (A, 
C), or with either a control-siRNA (siControl) or siQKI (B, D). A., B. Supernatants harvested 24 hours after LPS treatment were 
analyzed by ELISA assay for the indicated cytokines. Values were normalized to Control. *P = 0.069; **P < 0.019; ***P < 0.001. C.-D. 
Phosphorylation of Erk1/Erk2, Jnk1/Sapk and p38 Mapk following LPS stimulation was followed on Western blots. Stripes in C. and D. 
come from three different gels prepared from the same extracts. HA: HA-tagged QKI. Vinculin (Vinc) was used as a loading control. 
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overexpression sharply increased the level of total 
p38, however only residual amount of this kinase was 
phosphorylated (Figure 3C). As the p38 MAPK pathway 
is central to the stabilization of many mRNAs encoding 
factors implicated in the innate and adaptive immune 
responses, including cytokines [24-26], these results 
further confirm our hypothesis that the early down-
regulation of Qki by LPS signaling pathway is needed for 
mounting an effective immune response.
miR-155 also targets QKI in human leukemic B 
lymphocytes
The expression of miR-155 is high in B-CLL-
derived cell lines as well as in CLL patients [27-30], but 
low in B-cell Burkitt’s lymphomas [31]. We found that 
QKI and miR-155 expression well discriminate Burkitt’s 
cell lines, all with lower miR-155 and higher QKI levels, 
from CLL cell lines, all with higher miR-155 but lower 
QKI levels (Figure 4A). Accordingly, QKI protein levels 
in MEC2, Ado-2199 and WAC CLL cells were lower 
than those in PH3R1, EW36 and BJAB cells (Figure 
4B). However, QKI levels in MEC1, Daudi and Raji cells 
suggest that QKI expression at the protein level is also 
regulated by other, non-miR-155-dependent mechanisms. 
Nevertheless, miR-155 mimic reduced QKI expression in 
BJAB and PH3R1 Burkitt’s cells, but not in MEC2 CLL 
cells (Figure 4C). In contrast, transfecting MEC2 cells 
with 155-I slightly but significantly increased QKI levels 
(Figure 4C). Altogether, these results indicate that QKI is 
also a target of miR-155 in B cells. 
Figure 4: Burkitt’s and CLL cell lines display different levels of QKI and miR-155 expression. A. QKI and miR-155 levels 
were measured by qRT-PCR in five Burkitt’s lymphoma cell lines (filled triangles) and in four CLL-derived cell lines (filled circles). B. QKI 
protein levels in the same cells as in A.. C. Indicated cells were transfected with either a Control RNA or miR-155. MEC2 cells were also 
transfected with 155-I. Western blot was performed 48 hours following transfection. Panels are from the same blot. 
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QKI regulates FAS expression and Caspases 3/7 
activity in B cells
A bioinformatics analysis showed that the 3’-UTR 
of FAS transcripts contains the consensus sequence for 
QKI binding [32]. siQKI, functional in both MEC2 and 
BJAB cell lines (Figure 5A), significantly reduced FAS 
levels and the percentage of Fas-expressing cells in both 
cell lines (Figure 5B, 5C). Furthermore, siQKI decreased 
FAS transcript levels in MEC2 but not BJAB cells (Figure 
5D), suggesting that different molecular mechanisms 
control FAS expression in these two types of hematological 
malignancies. Finally, siQKI decreased the activity of 
Caspases 3/7 in both cell lines (Figure 5E), suggesting that 
QKI might act as a TSG also in B cells.
QKI is implicated in lymphocyte function and 
homeostasis
We then analyzed transcriptome modifications 
induced by siQKI in MEC2 and BJAB cells using 
Affymetrix arrays (MIAME: E-MTAB-2375) and 
Figure 5: QKI effects on FAS expression and Caspases 3/7 activity in BJAB and MEC2 cells. Analyses were conducted 
48 hours following transfection. A. QKI transcripts levels were determined using qRT-PCR. *siQKI different from siControl, P < 0.0003 
(n = 3). B. Representative histograms of FAS staining on MEC2 and BJAB cells as determined by flow cytometry (n = 3). C. Graphical 
presentation of triplicate results of flow cytometry run in B.. *P < 0.026 (n = 3). D. FAS expression was analyzed using qRT-PCR. *P < 
0.01. E. The relative rate of Caspases 3/7 activity was measured in cells transfected either with siQKI or siControl. *P < 0.031. In A. and 
C.-E., values for siControl were arbitrarily set to 1.
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Ingenuity software. Expectedly, pathways implicated in 
the regulation of lymphocyte differentiation, proliferation, 
function and/or signaling were affected in both cell lines 
(not shown). However, siQKI had also cell specific 
effects (Tables 1 and 2). Of interest, the p38 pathway, 
and particularly IRAK3 expression were affected by 
siQKI in MEC2 cells (Table 1). This result and those of 
Figures 3C, 3D, suggest that p38 pathway is regulated by 
QKI in different types of hematopoietic cells. Of note, 
30% of the 100 transcripts, most significantly affected 
by siQKI in MEC2 cells were predicted targets of miR-
155 (Supplementary Table 2), versus 23% in BJAB cells 
(Supplementary Table 3). Thus, variations in QKI levels 
in B cells (Figure 4) are likely to be instrumental in both 
Burkitt’s and CLL cell transformation.
QKI is downregulated in B cells of CLL patients
QKI being a target of miR-155 at least in certain 
conditions, we would expect its expression to be reduced 
in leukemias presented with high miR-155 levels, such 
as CLL or AML [27-30, 5]. Indeed, the levels of QKI 
transcripts were significantly lower in CLL patients 
(Figure 6A). In agreement with this result, publicly 
available array data show that in both, CLL and AML 
patients, the expression of QKI is significantly reduced as 
compared with healthy donors (data not shown). Finally, 
Qki levels were also lower in B cells of Eµ-miR-155 
transgenic mice at the most advanced stage of leukemia 
(Figure 6B). These results suggest that the disruption 
of cross-regulations between QKI, miR-155 and factors 
implicated in the immune response, may generally be 
associated with B cell leukemic transformation.
DISCUSSION
We found that Qki levels are reduced at the onset 
of immune response to LPS, when miR-155 levels are 
on the rise, positioning Qki as an immune factor and 
a target of miR-155. In addition, we found that QKI 
overexpression increases IL-10 production, as well as 
the total amount of p38, while markedly impairing p38 
phosphorylation. It is highly probable that following LPS 
stimulation, cells sensing the lack of p38 phosphorylation 
in the presence of excess QKI increase their levels of 
total p38 to compensate for this deficiency. Of note, 
K-Ras similarly was previously shown to induce p38 
expression but not its phosphorylation, and higher levels 
of unphosphorylated p38 promote Ras transformation in 
rat intestinal epithelium through an increased complex 
formation with Erk-1, -2 kinases [33]. As the reduction of 
Qki levels only took place at the first hours of the immune 
response, we hypothesize that miR-155 targeting of Qki is 
restricted only at the beginning of the response, to allow 
p38 MAPK required activation following LPS challenge. 
It is thus very likely that during the first hours of LPS 
signaling, dose-dependent effects take place between Qki, 
miR-155 and MAPKs activity, paralleling the oscillatory 
activity of “early” genes, such as NF-κB and AP-1 activity 
[34]. Similarly, low miR-155 expression at the early phase 
of dendritic cells maturation enables the activation of the 
p38 pathway, thus favoring IL-1 expression and signaling 
cascade [35].
Later on, the miR-155 targeting of Qki transcript was 
impaired. This might be due to the fact that proliferating 
cells, including human monocytes stimulated with LPS 
and IFNγ, tend to express mRNAs with shortened 3’-
UTR and consequently fewer miRNA target sites [36]. 
Alternatively, Qki 3’-UTR might act as a sponge for miR-
155. Finally, miR-155 overexpression in MCF7 breast 
cancer cells increases the levels of some of its target 
Figure 6: A. RNAs extracted from B cells purified from 10 
healthy donors (HD), 38 patients with indolent CLL (IND) and 
72 patients with aggressive CLL (AGG) were analyzed by qRT-
PCR. Boxes include values from the first to the third quartiles; o, 
extreme data points; +, median; x, mean ± SD. B. Qki expression 
in B cells purified from the spleens of wild type or Eµ-miR-155 
transgenic mice was analyzed by Western blotting. Panels are 
from the same blot. Qki/Gapdh ratios are given under each lane. 
Spleens from Eµ-miR-155 mice were: pre-leukemic (1 and 2); 
and leukemic (3 and 4).
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transcripts through the progressive shortening of their 3’-
UTR, including p38 MAPK [37]. 
Our results show that QKI overexpression increased 
IL-10 expression and affected p38 MAPK, while siQKI 
modulated the expression of IRAK3, a negative regulator 
of TLR signaling, including p38 MAPK [38]. Altogether, 
these results suggest that QKI, miR-155, p38 and IL-10 
[39] are involved in a common regulatory circuitry in 
B cells and macrophages, and that QKI may represent 
a new factor of hematopoietic cell transformation. This 
hypothesis is also supported by previous findings showing 
that the expression of QKI isoforms, changes significantly 
during hematopoietic differentiation, suggesting for a 
critical role of QKI in hematopoiesis and function [23].
Our results further show an inverse correlation 
between QKI and miR-155 expression in CLL and 
Burkitt’s cell lines, and establish that QKI might render 
B cells prone to cell death by increasing Caspase3/7 
signaling and FAS expression, suggesting that QKI may 
behave as a TSG in B cells. Importantly, QKI expression 
was low in CLL patients, known to have high levels of 
miR-155 [27-30], as well as in leukemic B cells isolated 
from the spleens of Eµ-miR-155 mice, results further 
supported by data available in public databases.
Finally, QKI unusually long 3’-UTR contains 
target sites for most miRNAs (targetscan.org). Thus, QKI 
may represents a regulatory hub directing many cellular 
processes. As human QKI 3’-UTR contains three miR-155 
target site, the third one being present only in apes, where 
QKI came to represent the first most probable target of 
miR-155, one can expect miR-155 - QKI cross-regulatory 
interactions to have gained a critical importance in this 
group. 
Mice with spontaneous deletion of Qki have marked 
rapid tremor and seizures, and their entire central nervous 
system is severely depleted in myelin [40]. As miR-155 
expression is elevated in neuro-inflammatory pathologies 
such as MS or ALS [41, 42], our data further suggest that 
a lack of QKI anti-inflammatory input may result in the 
deleterious dominance of miR-155 activity, therefore, 
miR-155-QKI interactions could prove to be significantly 
important for future therapies aimed at neuro-degenerative 
pathologies presented with high levels of miR-155. 
In conclusion, while miR-155 is critical for 
mounting an effective immune response, its prolonged 
expression under chronic inflammatory conditions drives 
immune pathologies and leukemias. Therefore, a better 
understanding of miR-155/QKI functions and their control 
of expression in immune cells should allow to design new 
miR-155-based cancer immunotherapies. Our findings 
suggest that when QKI-miR-155 reciprocal regulation 
becomes dysfunctional, enhanced miR-155 activity drives 
tumor development and evasion of the immune response.
Supplementary information is available at 
Oncotarget website.
MATERIALS AND METHODS
Affymetrix microarray (Santa Clara, CA, USA) 
analyses were submitted to the MIAME database 
(accession number E-MTAB-2375). Purified CD19+ 
B cells were purchased from Sanguine BioSciences 
(Sherman Oaks, CA, USA). Eμ-miR-155 transgenic 
mice were previously described [6]. B cells from mice 
were isolated using B-cell purification kit from Miltenyi 
Biotech (San Diego, CA, USA).
Cells were grown following standard procedures. 
Information for miRNAs and siRNAs is found in 
Supplementary Table 1. The fragments of QKI 3’UTR 
and the Luciferase reporter construct containing the 
promoter of QKI gene were purchased from SwitchGear. 
Each miR-155 site was subsequently mutated using the 
Quick-Exchange Mutagenesis kit (Agilent; Santa Clara, 
CA, USA). Human QKI-5 cDNA was purchased from 
Genecopeia (Rockville, MD, USA) and recloned into the 
pCMV-HA expression vector. 
Luciferase assays were run 48 hours after 
transfection as previously described [43]. Caspase-
Glo 3/7 kit (Promega; Madison, WI, USA) was used to 
measure cell death. The assays were performed three 
times in quadruplicate, and the mean ± S.D. of caspase 
3/7 activation (expressed as arbitrary units) is shown. 
RNAs were extracted either with TRIzol (Life 
Technologies) or the RNA purification kit from Norgen 
(Thorold, ON, Canada). They were subsequently subjected 
to DNase digestion (Turbo-DNase- Life Technologies). 
MiRNA and gene qRT-PCRs were respectively performed 
using the corresponding Assays from Life Technologies 
(Supplementary Table 1). RT-PCRs were run in triplicates. 
Values were normalized using one of the following 
normalizers: RNU-44, RNU-48, RNU-6B or U6 for 
MiRNA assays and OAZ1, β-Actin or GAPDH for Gene 
Expression assays.
Antibodies and other related information are listed 
in Supplementary Table 1. Flow cytometry staining was 
done following standard procedures and run on a Calibur 
(BD-Biosciences) machine. The data were analyzed 
using FloJow (Ashland, OR, USA) software. Cytokine 
production was measured using the ELISA kit (Qiagen) 
following manufacturer’s instruction. Statistical analysis 
were done using the Student t test, and P values are 
provided in the Figure legends. 
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